ASO Author Reflections: Multimodality Treatment of Cutaneous Angiosarcoma

More aggressive multimodality treatment for this aggressive disease seems warranted to improve outcomes.3 Adding neoadjuvant or adjuvant RT, with or without hyperthermia, might already improve local recurrence-free survival.2,4 Moreover, strategies to include neoadjuvant or adjuvant systemic treatment such as paclitaxel in this setting seems the next step to improve distant metastases-free survival.5 Preferably, this should be done in a prospective study, although this might be difficult for a rare cancer like cAS. Therefore, the next best could be to collect real-world evidence from specialized sarcoma centers to learn how to improve treatment of this devastating disease.

留言 (0)

沒有登入
gif